Get the Stockscreener App
8.99
4.29%
0.37
Neuropace Inc stock is traded at $8.99, with a volume of 156.23K.
It is up +4.29% in the last 24 hours and down -3.85% over the past month.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.
See More
Previous Close:
$8.62
Open:
$8.65
24h Volume:
156.23K
Relative Volume:
0.46
Market Cap:
$297.40M
Revenue:
$65.42M
Net Income/Loss:
$-32.96M
P/E Ratio:
-7.0787
EPS:
-1.27
Net Cash Flow:
$-19.87M
1W Performance:
+5.02%
1M Performance:
-3.85%
6M Performance:
-34.71%
1Y Performance:
+28.25%
1-Day Range:
$8.65
$9.17
1-Week Range:
$8.17
$9.17
52-Week Range:
$5.45
$18.98
Neuropace Inc Stock (NPCE) Company Profile
Name
Neuropace Inc
Sector
Industry
Phone
(650) 237-2700
Address
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Compare NPCE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
8.99 | 278.55M | 65.42M | -32.96M | -19.87M | -1.27 |
|
ABT
Abbott Laboratories
|
132.59 | 226.73B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.17 | 152.69B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
394.22 | 145.89B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.71 | 118.91B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
81.83 | 45.97B | 5.69B | 1.41B | 577.90M | 6.95 |
Neuropace Inc Stock (NPCE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-25 | Initiated | H.C. Wainwright | Buy |
| Jan-21-25 | Initiated | UBS | Buy |
| Mar-14-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-30-24 | Initiated | Leerink Partners | Outperform |
| Nov-10-23 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-24-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-22-23 | Initiated | Lake Street | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-19-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-07-22 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-11-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-18-21 | Initiated | Robert W. Baird | Outperform |
| May-17-21 | Initiated | JP Morgan | Overweight |
| May-17-21 | Initiated | Morgan Stanley | Overweight |
| May-17-21 | Initiated | SVB Leerink | Outperform |
| May-17-21 | Initiated | Wells Fargo | Overweight |
View All
Neuropace Inc Stock (NPCE) Latest News
Neuropace (NPCE) Stock: A Bearish Crossroads of Technical and Fundamental Risks - AInvest
FY2029 EPS Estimates for NeuroPace Raised by Leerink Partnrs - MarketBeat
Leerink Partnrs Expects Increased Earnings for NeuroPace - MarketBeat
What is HC Wainwright's Forecast for NeuroPace Q1 Earnings? - MarketBeat
Lord Abbett & CO. LLC Takes Position in NeuroPace, Inc. $NPCE - MarketBeat
Wells Fargo & Company Lowers NeuroPace (NASDAQ:NPCE) Price Target to $15.00 - MarketBeat
Equities Analysts Set Expectations for NeuroPace Q3 Earnings - MarketBeat
Deutsche Bank AG Has $11.36 Million Holdings in NeuroPace, Inc. $NPCE - MarketBeat
Moving Average Crossover Confirms Uptrend in NeuroPace Inc.July 2025 Weekly Recap & AI Enhanced Execution Alerts - newsyoung.net
AI Trend Models Suggest Bounce for NeuroPace Inc.July 2025 Weekly Recap & High Accuracy Buy Signal Tips - newsimpact.co.kr
NeuroPace Inc. stock daily chart insightsPortfolio Gains Report & Weekly Market Pulse Alerts - Newser
Q3 Earnings Estimate for NeuroPace Issued By HC Wainwright - Defense World
NeuroPace (NASDAQ:NPCE) Posts Quarterly Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
How hedge fund analytics apply to NeuroPace Inc. stockMarket Activity Summary & Low Risk High Win Rate Stock Picks - Newser
Will NeuroPace Inc. bounce back from current supportJuly 2025 EndofMonth & Capital Protection Trading Alerts - Newser
Regression analysis insights on NeuroPace Inc. performanceWeekly Gains Summary & Stepwise Trade Signal Implementation - Newser
Is NeuroPace Inc. stock ready for a breakoutTrade Risk Assessment & Low Volatility Stock Recommendations - Newser
Price momentum metrics for NeuroPace Inc. explainedMarket Movement Recap & Expert Approved Momentum Ideas - Newser
NeuroPace FY2025 EPS Estimate Boosted by Cantor Fitzgerald - MarketBeat
What risks could impact NeuroPace Inc. stock performance2025 Top Gainers & Daily Price Action Insights - Newser
Why NeuroPace Inc. stock attracts strong analyst attentionPortfolio Performance Summary & Fast Moving Stock Trade Plans - Newser
Cantor Fitzgerald Boosts Earnings Estimates for NeuroPace - Defense World
What is HC Wainwright’s Forecast for NeuroPace Q1 Earnings? - Defense World
FY2025 EPS Estimates for NeuroPace Lifted by Leerink Partnrs - Defense World
Neuropace’s Innovative Approach to Treating Lennox-Gastaut Syndrome - MSN
Reversal indicators forming on NeuroPace Inc. stockJuly 2025 Breakouts & Safe Capital Growth Tips - Newser
Is NeuroPace Inc. in a long term uptrend2025 AllTime Highs & High Accuracy Swing Entry Alerts - thegnnews.com
NeuroPace, Inc. (NASDAQ:NPCE) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year - simplywall.st
NeuroPace stock price target lowered to $13 by Wolfe Research - Investing.com South Africa
Wells Fargo Reaffirms Buy Rating on NeuroPace with $15 Price Target - AInvest
Wells Fargo Maintains NeuroPace(NPCE.US) With Buy Rating, Cuts Target Price to $15 - 富途牛牛
Lake Street Maintains NeuroPace(NPCE.US) With Buy Rating, Maintains Target Price $20 - 富途牛牛
NeuroPace, Inc. (NASDAQ:NPCE) Q2 2025 Earnings Call Transcript - Insider Monkey
NeuroPace Q2 Loss Wider Than Expected, Revenue Exceeds ForecastsNews and Statistics - IndexBox
NeuroPace 2025 Q2 Earnings Revenue Growth Amid Sustained Net Loss - AInvest
NeuroPace stock price target lowered to $15 by Wells Fargo on wider loss forecast - Investing.com South Africa
NeuroPace Inc.: Q2 Earnings Snapshot - Connecticut Post
NeuroPace Expects FDA Submission for Expanded IGE Indication in 2H 2025 - AInvest
NeuroPace Q2 Revenue Hits $23.5M, Up 22% YoY, With Gross Margin at 77.1% - AInvest
NeuroPace Inc (NPCE) Q2 2025 Earnings Call Highlights: Record Revenue and Strategic Growth ... By GuruFocus - Investing.com Canada
NeuroPace Reports Record Revenue and Raises Guidance - TipRanks
Is NeuroPace Inc. in Accumulation Phase NowAI Based High Gain Watchlist Scanner Shared - beatles.ru
NeuroPace Q2 2025 Earnings Call Transcript - MarketBeat
NeuroPace raises 2025 revenue guidance to $94M-$98M as RNS System drives record growth - MSN
NeuroPace: Building a Durable Moat in Epilepsy Treatment with AI-Driven Innovation and Expanding Indications - AInvest
NeuroPace Revenue Jumps 22 Percent in Q2 - Nasdaq
NeuroPace Raises 2025 Revenue Guidance to $94M-$98M, Driven by RNS System Growth - AInvest
NeuroPace's Q2 2025 Earnings Call: Unraveling Key Contradictions in Growth, Margins, and Strategy - AInvest
NeuroPace, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:NPCE) - Seeking Alpha
Neuropace Inc Stock (NPCE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Neuropace Inc Stock (NPCE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Morrell Martha | CHIEF MEDICAL OFFICER |
Feb 21 '25 |
Sale |
13.72 |
78,334 |
1,074,844 |
81,993 |
| KCK LTD. | 10% Owner |
Feb 20 '25 |
Sale |
9.40 |
5,270,845 |
49,545,943 |
0 |
| Morrell Martha | CHIEF MEDICAL OFFICER |
Jan 30 '25 |
Sale |
15.00 |
200 |
3,000 |
86,762 |
| Morrell Martha | CHIEF MEDICAL OFFICER |
Jan 29 '25 |
Sale |
15.00 |
100 |
1,500 |
86,962 |
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):